HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
QNTM
Quantum BioPharma Ltd.
There isn't enough reported data to score QNTM yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
QNTM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
QNTM's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
QNTM PE Valuation
QNTM has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
QNTM Forward outlook
There aren't enough analyst estimates for QNTM to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
QNTM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2019 | -$336.79 | -$208.14 |
QNTM and HIMS do not have enough comparable growth data to identify a winner.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
QNTM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2019 | $180.8K | +32704% |
QNTM's revenue has grown year over year for four quarters in a row: $180,750 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2019 | -14263% | N/A |
| Q4 2018 | -769630% | N/A |
| Q3 2018 | -21824% | N/A |
| Q2 2018 | -11697% | N/A |
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the stronger cash trend. Its trailing FCF is down 84% versus its history, compared with QNTM at down 823%.
QNTM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2019 | -$13.2M | -$11.3M |
| Q4 2018 | -$1.9M | -$1.9M |
| Q3 2018 | $3.1M | +$3.1M |
| Q2 2018 | -$1.6M | -$1.6M |
| Q1 2018 | -$2.4M | -$2.4M |
| Q4 2017 | -$2.6K | -$845 |
| Q3 2017 | -$2.5K | -$1.1K |
QNTM has burned cash in almost every quarter: −$14M over the past year, against −$2M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over QNTM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
QNTM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +4.1K shares |
| 1 year | +7.5% | +7.6K shares |
QNTM has 108,558 diluted shares, up 7.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2018 | — |
| Q3 2018 | — |
| Q2 2018 | — |
| Q1 2018 | — |
| Q4 2017 | — |
| Q3 2017 | — |
| Q2 2017 | — |
| Q1 2017 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
QNTM Net Leverage
QNTM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
QNTM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.2 | Neutral |
| Stochastic | 6.2 | Oversold |
QNTM's weekly RSI is 36 (neutral) and its Stochastic is 6 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
QNTM PE vs Healthcare Sector
QNTM has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
QNTM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.65 | 33% below |
| 20 week MA | $3.05 | 42% below |
| 50 week MA | $4.41 | 60% below |
| 100 week MA | $8.36 | 79% below |
| 200 week MA | $30.3 | 94% below |
QNTM is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over QNTM on returns for 2026, with the stronger performance.
QNTM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $364.0 | $109.9 | -70% |
| 2021 | $109.9 | $67.0 | -39% |
| 2022 | $67.0 | $50.1 | -25% |
| 2023 | $50.1 | $59.8 | +19% |
| 2024 | $59.8 | $4.06 | -93% |
| 2025 | $4.06 | $8.30 | +104% |
| 2026 YTD | $8.30 | $1.78 | -79% |
QNTM's yearly returns have swung widely, from +104% in 2025 to −93% in 2024. It's down 79% so far in 2026.